ReCode Therapeutics
1140 O'Brien Drive
Menlo Park, CA 94025
United States
Tel: 408-585-1700
Website: https://recodetx.com/
Email: info@recodetx.com
About ReCode Therapeutics
The Why Behind Our Work
We imagine a world where people living with genetic diseases can fully benefit from the promise of genetic medicines. Our novel mRNA and gene correction therapeutics have the potential to make this a reality.
Therapeutic Areas of Focus
Cystic fibrosis
Primary ciliary dyskinesia
Certain cancers and central nervous system (CNS) diseases
Power the Next Wave of Genetic Medicine
We are one of the rare companies whose innovations are poised to fundamentally shift an entire class of medicine.
Join us as we advance our pipeline into clinical development and scale ReCode’s next-generation genetic medicines delivery platform and pipeline.
53 articles about ReCode Therapeutics
-
This week money went towards more advanced rounds of financing for drugs and technology that have already shown a lot of promises.
-
ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M
6/29/2022
ReCode Therapeutics announced the close of a Series B extension financing round, co-led by new investors, Leaps by Bayer, the impact investment unit of Bayer AG, AyurMaya, an affiliate of Matrix Capital Management, and with participation from Amgen Ventures.
-
ReCode Therapeutics to Present at Jefferies Healthcare Conference
6/3/2022
ReCode Therapeutics , a biopharmaceutical company powering the next wave of genetic medicines through superior delivery, today announced that David Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics will present a corporate overview on Friday, June 10th from 11:00 - 11:25 a.m. ET at the Jefferies Healthcare Conference being held in New York, NY from June 8-10, 2022.
-
ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference
5/15/2022
ReCode Therapeutics, a biopharmaceutical company powering the next wave of genetic medicines through superior delivery presented new preclinical data from the company’s inhaled mRNA-based molecular therapy program for the treatment of primary ciliary dyskinesia in three posters at the American Thoracic Society 2022 International Conference, taking place May 13-18, 2022 in San Francisco.
-
ReCode Therapeutics to Present at 2022 RBC Capital Markets Global Healthcare Conference
5/10/2022
ReCode Therapeutics , a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) lipid nanoparticle (LNP) delivery platform, today announced that David Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat on Tuesday, May 17th from 2:05 - 2:30 p.m. ET.
-
ReCode Therapeutics to Present Preclinical Data Using Proprietary SORT LNP Delivery Platform From Its mRNA-based Therapeutic Programs at the ATS 2022 International Conference in San Francisco
5/3/2022
ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its selective organ targeting (SORT) lipid nanoparticles (LNP) delivery platform, today announced that it will present preclinical data from its mRNA-based therapeutic programs in cystic fibrosis and primary ciliary dyskinesia at the American Thoracic Society’s ATS 2022 International Conference.
-
ReCode Therapeutics to Present at Oppenheimer 32nd Annual Healthcare Conference
3/9/2022
ReCode Therapeutics announced that Shehnaaz Suliman, M.D., MBA, M.Phil, chief executive officer of ReCode Therapeutics will present a corporate overview at the upcoming Oppenheimer 32nd Annual Healthcare Conference being held virtually from March 15-16, 2022.
-
Suliman anticipates filing an Investigational New Drug application with the FDA for the PCD asset this year, and next year filing one for the cystic fibrosis asset.
-
ReCode Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
1/10/2022
ReCode Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference.
-
ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer
1/10/2022
ReCode Therapeutics today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today.
-
ReCode Therapeutics to Participate in Upcoming November Investor Conferences
11/8/2021
ReCode Therapeutics today announced that Company leadership will participate in two upcoming virtual investor conferences in November: 2021 Stifel Healthcare Conference Format: Live Presentation Date: Monday, November 15, 2021 Time: 4:40 p.m.
-
ReCode Therapeutics Presents Preclinical Data from mRNA-based Cystic Fibrosis Program at 2021 North American Cystic Fibrosis Conference
11/3/2021
ReCode Therapeutics presented new preclinical data today from the Company’s inhaled mRNA-based therapeutic program for cystic fibrosis (CF) during an oral poster session at the 2021 North American Cystic Fibrosis Conference (NACFC).
-
Money on the Move: October 20 – 26
10/27/2021
While the volatility of the market has some shying away from going public, private investment dollars are still rolling in each week. Check out our top picks. -
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million
10/21/2021
ReCode Therapeutics today announced the closing of an $80 million Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
-
ReCode is aiming to advance its lead candidates for cystic fibrosis and primary ciliary dyskinesia (PCD).
-
ReCode Therapeutics to Present Preclinical Data from mRNA-based Program for Cystic Fibrosis at Upcoming Virtual 2021 North American Cystic Fibrosis Conference
10/19/2021
ReCode Therapeutics today announced that it will present preclinical data from its mRNA-based therapeutic program for cystic fibrosis (CF) in a poster presentation at the upcoming 2021 North American Cystic Fibrosis Conference (NACFC) to be held virtually from November 2-5, 2021.
-
ReCode Therapeutics Announces Participation in Upcoming October Investor Conferences
9/28/2021
ReCode Therapeutics today announced that Company leadership will participate in three upcoming virtual investor conferences in October: Chardan 5th Annual Genetic Medicines Conference Format: Presentation Date: Monday, October 4, 2021
-
ReCode Therapeutics Appoints Nicholas P. France, M.D., as Senior Vice President of Clinical Development
9/27/2021
ReCode Therapeutics today announced the appointment of Nicholas P. France, M.D., MRCPCH, as senior vice president, clinical development.
-
ReCode Therapeutics Announces Participation in Upcoming Investor Conferences
9/3/2021
ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that Company leadership will participate in three upcoming virtual investor conferences.
-
ReCode Therapeutics Appoints Angèle Maki, Ph.D., as Senior Vice President of Business Development
8/16/2021
ReCode Therapeutics today announced the appointment of Angèle Maki, Ph.D., as senior vice president, business development.